The development of innovative, biologically complex, and personalized therapies has led to unexpected challenges in predicting which patients will benefit from these therapies or develop immune-related adverse events or relapse. Monitoring biomarkers in all drug development steps is bringing objective and efficient support to these critical questions and has a recognized role and value in decision-making (Bio Industry Analysis 2015). However, biomarker analysis also has its specific challenges, and it is critical to understand the context-of-use of the biomarker to select the most appropriate assay.
Active Biomarkers relies on one of the most complete technological park in Europe, allowing us to deal with the challenges specific to each sample, should it be related to:
- High / Ultra Sensitivity
- Low volume of sample
- High throughput
Download our case study on the qualification of an ultra-sensitive assay on Simoa platform